ARTICLE | Product Development
AZ’s Enhertu data highlight value of continued HER2 innovation
And set a new efficacy standard in second-line, HER2-positive breast cancer
September 21, 2021 1:29 AM UTC
It’s no surprise that AstraZeneca’s Enhertu outperformed Kadcyla in a head-to-head second-line breast cancer trial, but the magnitude of the progression-free survival advantage went well beyond expectations and represents the kind of meaningful advance that industry is striving for with next-generation modalities.
It also showcases the untapped value still present in the established target HER2, which is in the crosshairs of many next-generation antibody developers...
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)